6/2/2014 10:54:26 AM
Oxford, UK – 2 June 2014. Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced that following its acquisition of Cytocell in March, it will directly sell Cytocell products to the North American market from the 1st June 2014. New and existing Cytocell customers in North America will now benefit from OGT’s expert and experienced sales and support infrastructure, which will be further enhanced through additional appointments in the coming months.
OGT’s acquisition of Cytocell saw the addition of a portfolio of Fluorescence In Situ Hybridisation (FISH) probes to its CytoSure™ cytogenetics array and Genefficiency™ next generation sequencing products and services, expanding the company’s genomic medicine offering.
Dr Martin Lawrie, Managing Director of Cytocell said: “The global cytogenetics market is predicted to grow by 23% a year to $2 billion by 2019, and with North America accounting for approximately 50% of the market, OGT is now well placed to better serve this increasing customer base with a wider range of products. The integration of Cytocell into the OGT group has proceeded extremely smoothly with very positive, immediate benefits for our customers. OGT’s excellent and expanding sales team will provide our customers with the best possible sales and support experience moving forward.”
In June, scientists can find out about OGT’s extended genomic medicine portfolio at:
• International Collaboration for Clinical Genomics Conference, 11-12 June, Bethesda, MD, USA
• Association of Genetic Technologists 39th Annual Meeting, 12-14 June, Louisville, KY, USA
For further information please visit www.ogt.com.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684
E: email@example.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech
About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™ and Genefficiency™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products and services deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease.
For more information on the Company, please visit our website at www.ogt.com
CytoSure™ and Genefficiency™ NGS browser/report: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
Help employers find you! Check out all the jobs and post your resume.
comments powered by